Torsdag 31 Oktober | 13:15:09 Europe / Stockholm
2024-10-03 08:58:14

The trial was made with the company's lead candidate, CS1, in the rare cardiovascular disease Pulmonary Arterial Hypertension. See Sten R Sörensen, CEO, announce the results and their impact on Cereno Scientific.

See the interview at biostock.se:
https://www.biostock.se/en/2024/10/cereno-scientific-discusses-phase-iia-results-for-cs1/
This is a press release from BioStock - Connecting Innovation & Capital.